Theaprin Pharmaceuticals Inc.

Alkermes Pharma Ireland Limited

Alkermes, Inc.

Context Biopharma Inc.

Carefusion 213, LLC

Harry G Brittain

Philip V Felice

J Michael Ramstack

Steven G Wright

Joyce M Hotz

Shawn L Lyons

David A Dickason

Peter F Sharkey

Alan B Miller

Stefan Proniuk

Javad Parvizi

Craig J Della Valle

David L Kirschman

Mayank M Parmar

A ready-to-use, gamma-ray sterilized, surgical antiseptic composition comprising an initial non-toxic concentration of povidone-iodine above a minimum effective concentration of available iodine, iodide in sufficient quantity to provide donor iodine upon gamma irradiation to stabilize said povidone-iodine and maintain said minimum effective concentration of available iodine, and a buffered saline solution.

Ready-to-use, terminally sterile packaging for surgical antiseptic and method of use

A platform drug delivery system and a method of improving the delivery of low solubility pharmaceuticals utilizing crystal engineering and Theanine dissolution resulting in enhanced bioactivity, dissolution rate, and solid state stability.

Platform drug delivery system utilizing crystal engineering and theanine dissolution

Amorphous forms of onapristone and methods of making such amorphous forms are provided. Amorphous forms can be characterized by their X-ray powder diffraction patterns and other properties.

Amorphous onapristone compositions and methods of making the same

Cocrystal compositions of metoprolol and dabigatran bases with enantiomers of theanine.

Characterization of the cocrystal products formed by metoprolol and dabigatran bases with L-theanine

This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.

Polymorphic forms of naltrexone

Methods of making cocrystal compositions of metoprolol and dabigatran bases with enantiomers of theanine.

A method of making a water-soluble doxorubicin-theanine cocrystal composition. The method includes the steps of providing a quantity of doxorubicin, adding a quantity of a theanine enantiomer to the quantity of doxorubicin to form a mixture of the quantity of doxorubicin and the enantiomer of theanine, wetting the mixture, and grinding the mixture for a length of time sufficient to produce a dried crystalline mass.

A method of treating Hodgkin's disease in a subject. The method involves administering to the subject an effective amount of a water-soluble composition which includes a cocrystal composition containing doxorubicin and a theanine enantiomer.

This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.

A method of treating high grade temperature using a water-soluble cocrystal composition contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer selected from an alpha variant of theanine or a beta variant of theanine or other form of theanine.

Growing community of inventors

Milford, NJ, United States of America

Harry G Brittain